Group 1: Company Overview - Consolidated Edison (ED) is one of 107 individual stocks in the Utilities sector, ranking 5 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] Group 2: Performance Metrics - Consolidated Edison has gained approximately 14.5% year-to-date, outperforming the Utilities sector average return of 11.1% [4] - The Zacks Consensus Estimate for ED's full-year earnings has increased by 0.2% over the past quarter, reflecting improved analyst sentiment [4] Group 3: Industry Context - Consolidated Edison belongs to the Utility - Electric Power industry, which includes 58 individual stocks and currently ranks 87 in the Zacks Industry Rank [6] - The Utility - Electric Power industry has gained an average of 12.1% year-to-date, indicating that Consolidated Edison is performing better than its industry peers [6]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sc ...

Core Viewpoint - SS&C Technologies (SSNC) has experienced significant selling pressure, resulting in a 16% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential rebound for the stock [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if SSNC is oversold, with a current RSI reading of 28.14, suggesting that the stock may soon reverse its downward trend [2][5]. - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify potential price reversals, indicating that SSNC may present an entry opportunity for investors [3]. Group 2: Fundamental Indicators - Analysts have raised earnings estimates for SSNC by 2.7% over the last 30 days, reflecting a strong consensus among sell-side analysts, which typically correlates with price appreciation in the near term [7]. - SSNC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround in the stock's performance [8].

Core Viewpoint - Expedia (EXPE) has experienced a significant decline of 25.4% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory, supported by analysts predicting better earnings than previously expected [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - EXPE's current RSI reading is 27.59, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential reversal in the stock's trend [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for EXPE have increased by 2% over the last 30 days, which typically correlates with price appreciation in the near term [7]. - EXPE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].

For the quarter ended December 2025, Somnigroup International (SGI) reported revenue of $1.87 billion, up 54.7% over the same period last year. EPS came in at $0.72, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of -3.24% over the Zacks Consensus Estimate of $1.93 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +0.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Cardinal Health (CAH) .Cardinal currently has an average brokerage recomme ...

Core Insights - Medtronic reported $9.02 billion in revenue for the quarter ended January 2026, marking an 8.7% year-over-year increase and a surprise of +1.35% over the Zacks Consensus Estimate of $8.9 billion [1] - The earnings per share (EPS) for the same period was $1.36, slightly down from $1.39 a year ago, with an EPS surprise of +2.07% compared to the consensus estimate of $1.33 [1] Revenue Breakdown - U.S. Revenue: $4.49 billion, a 6% year-over-year increase, but below the average estimate of $4.59 billion [4] - International Revenue: $4.52 billion, exceeding the average estimate of $4.3 billion [4] - Cardiovascular Revenue: $3.46 billion, a 13.8% year-over-year increase, surpassing the average estimate of $3.39 billion [4] - Neuroscience Revenue: $2.56 billion, a 4.1% year-over-year increase, slightly below the average estimate of $2.58 billion [4] - Medical Surgical Revenue: $2.17 billion, a 4.9% year-over-year increase, exceeding the average estimate of $2.14 billion [4] - Diabetes Revenue: $796 million, a 14.7% year-over-year increase, surpassing the average estimate of $773.73 million [4] - Cardiac Rhythm & Heart Failure Revenue: $1.86 billion, a significant 20.1% year-over-year increase, exceeding the average estimate of $1.8 billion [4] Stock Performance - Medtronic shares have returned +2.8% over the past month, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - Labcorp Holdings reported revenue of $3.52 billion for the quarter ended December 2025, reflecting a 5.6% increase year-over-year [1] - The company's EPS for the quarter was $4.07, up from $3.45 in the same quarter last year, with an EPS surprise of +2.98% compared to the consensus estimate of $3.95 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $3.55 billion, resulting in a revenue surprise of -0.97% [1] Group 2 - Key metrics indicate that Labcorp's shares have returned +4.3% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Group 3 - The net book-to-bill ratio for Labcorp was reported at 1.1%, matching the average estimate based on two analysts [4] - Revenues from Biopharma Laboratory Services were $793 million, slightly above the average estimate of $791.05 million, representing a year-over-year change of +3.4% [4] - Revenues from Diagnostics Laboratories were $2.73 billion, below the average estimate of $2.77 billion, with a year-over-year change of +5.5% [4] - Adjusted Operating Income for Diagnostics Laboratories was $419.2 million, slightly below the average estimate of $423.58 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $136.1 million, exceeding the average estimate of $130.1 million [4] - Unallocated corporate expenses were reported at -$67.6 million, better than the average estimate of -$69.13 million [4]

Leidos (LDOS) reported $4.21 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 3.6%. EPS of $2.76 for the same period compares to $2.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $4.25 billion, representing a surprise of -1.07%. The company delivered an EPS surprise of +7.6%, with the consensus EPS estimate being $2.57.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Core Viewpoint - Extra Space Storage (EXR) is expected to report a year-over-year revenue increase in its fourth-quarter 2025 results, with no change in funds from operations (FFO) per share [1][10]. Financial Performance - In the last reported quarter, EXR achieved an FFO per share of $2.08, exceeding the Zacks Consensus Estimate of $2.06, driven by increased revenues from higher occupancy [2]. - The Zacks Consensus Estimate for quarterly property rental revenues is $731.87 million, up from $707.23 million in the same period last year [4]. - The estimate for revenues from tenant insurance is projected at $88.44 million, an increase from $83.70 million year-over-year [4]. - Management fees and other income are expected to rise to $32.09 million from $30.97 million in the previous year [4]. - Overall, the Zacks Consensus Estimate for total quarterly revenues stands at $864.48 million, indicating a 5.18% year-over-year growth [5][10]. Market Position and Challenges - EXR operates in a fragmented market with significant competition, facing challenges from price-sensitive customers and lower new customer rates, which may impact earnings [5][10]. - The self-storage industry is characterized as need-based and resilient to economic downturns, benefiting from favorable demographic trends [3]. Analyst Sentiment - Over the past four quarters, EXR has beaten the Zacks Consensus Estimate three times, with an average surprise of 0.76% [3]. - However, the consensus estimate for core FFO per share has decreased to $2.03, indicating no change from the previous year [6]. - The current Earnings ESP for EXR is -1.61%, and it holds a Zacks Rank of 4 (Sell), suggesting limited potential for a positive earnings surprise this quarter [8].